CEO summary: Experts convened by the Milken Institute, a nonpartisan think tank, assessed the readiness of the US healthcare system to adopt blood-based markers to aid in diagnosis of Alzheimer’s disease. They identified payer acceptance as a major hurdle, but clinical laboratory leaders should be encouraged by recent movement on that front. With the emergence […]
New Report Outlines Barriers to Alzheimer’s Blood Tests
Payer reluctance curbs adoption of new blood-based biomarker assays for the disease
- By Stephen Beale
- > From the Volume XXXIII, No. 11 - September 2026 Issue
